# Human Papillomavirus (HPV) Routine and Catch-up Vaccine Protocol

VACCINE PROTOCOL FOR age 9 to 45 years

**Document reviewed and updated:** **June 6, 2023**

## Condition for protocol

To reduce incidence of morbidity and mortality of cancers and pre-cancers caused by human papillomavirus infection of types 16, 18, 31, 33, 45, 52, and 58; and/or reduction of morbidity of genital warts caused by types 6 and 11.

## Policy of protocol

The nurse will implement this protocol for HPV vaccination.

## Condition-specific criteria and prescribed action

**Delete this entire paragraph before printing/signing protocol.**

[Instructions for persons adopting these protocols: The table below lists indication, contraindication, and precaution criteria and suggested prescribed actions that are necessary to implement the vaccine protocol. The prescribed actions include examples shown in brackets but may not suit your institution’s clinical situation and may not include all possible actions. A licensed prescriber must review the criteria and actions and determine the appropriate prescribing action.]

Indications

|  |  |
| --- | --- |
| Criteria | Prescribed action |
| Currently healthy person age 9 through 26 years. | Proceed to vaccinate if meets remaining criteria. |
| Person is less than age 9 years. | Do not give; have person return after turning at least 9 years of age. |
| Person is age 27 through 45 years. | Proceed to vaccinate after shared clinical decision-making. |
| Person is more than 1 month behind routine schedule. | Proceed to vaccinate if meets remaining criteria. Follow the catch-up schedule. |
| Person is already sexually active or may have acquired an HPV infection. | Proceed to vaccinate. [- Instruct person that s/he may have already become infected with one or more HPV types found in the vaccine and may not receive the full protective benefit of the vaccine.] [- Stress to all females the importance of receiving annual pap smears.] |
| Person has a chronic medical condition for which they receive regular medical care. | [Proceed to vaccinate. However, if the person has an immunocompromising condition, instruct them that the response to vaccination may be reduced.] |

Contraindications

|  |  |
| --- | --- |
| Criteria | Prescribed action |
| Person had a severe allergic reaction (anaphylaxis) to a previous dose of HPV vaccine. | Do not vaccinate. |
| Person has a severe allergy to a component of HPV vaccine, including yeast. | Do not vaccinate. |
| Person is pregnant. | Do not vaccinate; [instruct client to return when no longer pregnant]. |

Precautions

|  |  |
| --- | --- |
| Criteria | Prescribed action |
| Person has a mild illness defined as temperature less than \_\_\_\_°F/°C with symptoms such as: {to be determined by medical prescriber} | Proceed to vaccinate. |
| Person has a moderate to severe illness defined as temperature \_\_\_\_°F/°C or higher with symptoms such as: {to be determined by medical prescriber} | Defer vaccination and {to be determined by medical prescriber} |
| Person experienced syncope to previous vaccination or HPV vaccine. | [Proceed to vaccinate; however, ensure that person is either sitting or lying down during vaccination and monitor for [15] minutes following vaccination.] |

## Prescription

### Routine vaccination

* **Age 11-12 years (can start at age 9 years)**: Give 9vHPV, 0.5 mL, IM; 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon).
* **Immunocompromising conditions, including HIV infection:** 3-dose series, even for those who initiate vaccination at age 9 through 14 years, at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon).
* History of sexual abuse or assault: Start at age 9 years.

### Catch-up schedule, recommended for all persons through age 26 years

**2- or 3-dose series depending on age at initial vaccination**:

* Age 9 –14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon).
* Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months Minimum intervals (repeat dose if administered too soon):
  + Dose 1 to dose 2: 4 weeks
  + Dose 2 to dose 3: 12 weeks
  + Dose 1 to dose 3: 5 months

### Shared clinical decision-making

**Some adults age 27–45 years:** based on shared clinical decision-making.

* 3-dose series at 0, 1–2 months, 6 months
* Minimum intervals (repeat dose if administered too soon):
  + Dose 1 to dose 2: 4 weeks
  + Dose 2 to dose 3: 12 weeks
  + Dose 1 to dose 3: 5 months

## Medical emergency or anaphylaxis

Follow pre-established agency protocol for anaphylaxis.

## Question or concerns

**Insert overseeing medical consultant’s information below and delete this sentence before printing/signing.**

In the event of questions or concerns call (insert name) at (insert phone number).

**This protocol shall remain in effect until rescinded.**

Name of prescriber (please print):

Prescriber signature:

Date: